Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.
Clara Vollmer BarbosaHannah LangAnette MelkBernhard M W SchmidtPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)
NEPi + ACEi/ARBs are safe in terms of renal adverse events. Longer trials focusing on CKD are needed to evaluate the effect of NEPi on decreasing progression of CKD.
Keyphrases